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Abstract
Introduction: Breast cancer grows, metastasizes and relapses from rare, therapy resistant cells with a stem cell phenotype
(cancer stem cells/CSCs). However, there is a lack of studies comparing the functions of CSCs isolated using different
phenotypes in order to determine if CSCs are homogeneous or heterogeneous.
Methods: Cells with various stem cell phenotypes were isolated by sorting from Clone 66 murine breast cancer cells that
grow orthotopically in immune intact syngeneic mice. These populations were compared by in vitro functional assays for
proliferation, growth, sphere and colony formation; and in vivo limiting dilution analysis of tumorigenesis.
Results: The proportion of cells expressing CD44highCD24low/neg, side population (SP) cells, ALDH1+, CD49fhigh, CD133high,
and CD34high differed, suggesting heterogeneity. Differences in frequency and size of tumor spheres from these populations
were observed. Higher rates of proliferation of non-SP, ALDH1+, CD34low, and CD49fhigh suggested properties of transit
amplifying cells. Colony formation was higher from ALDH12 and non-SP cells than ALDH1+ and SP cells suggesting a
progenitor phenotype. The frequency of clonal colonies that grew in agar varied and was differentially altered by the
presence of MatrigelTM. In vivo, fewer cells with a stem cell phenotype were needed for tumor formation than ‘‘non-stem’’
cells. Fewer SP cells were needed to form tumors than ALDH1+ cells suggesting further heterogeneities of cells with stem
phenotypes. Different levels of cytokines/chemokines were produced by Clone 66 with RANTES being the highest. Whether
the heterogeneity reflects soluble factor production remains to be determined.
Conclusions: These data demonstrate that Clone 66 murine breast cancer cells that express stem cell phenotypes are
heterogeneous and exhibit different functional properties, and this may also be the case for human breast cancer stem cells.
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Introduction
An efficient mechanism of tissue maintenance, employed by
multiple normal tissues, is that of stem/progenitor cell self-renewal
with regulated production of differentiated functional progeny
(http://stemcells.nih.gov/info/). These processes occur in special-
ized microenvironments (stem cell niches), presumably to
minimize the production of potentially highly proliferative
abnormal cells outside the appropriate regulated site(s). A
prototypical normal tissue system is the regulated production of
blood and immune cells from hematopoietic stem cells (HSC) in
niches in the bone marrow [1].
The notion that tumors arise from rare cells with at least some
properties of stem cells has a long history. In 1974, Pierce
proposed that neoplasms might be derived from stem cells whose
proliferation or differentiation is dysregulated, or tumors might
develop from stem/progenitor cells that are displaced and/or
misregulated during development and later reactivated to form
tumors [2]. For example, failure of a testis to descend increases the
likelihood of its malignant transformation [3]. Dick’s laboratory
[4] applied techniques for isolating and assessing functions of
normal human hematopoietic stem cells to acute myelogenous
leukemia (AML) cells. They showed that only a small proportion of
the AML cells, not the majority population, were responsible for
maintenance of the tumor. These cells were termed AML stem
cells, or more generally, cancer stem cells (CSCs).
This concept has been extended to multiple other tumor types,
including solid tumors such as breast cancer [5–9] and hepato-
cellular carcinoma [10]. However, this generalization is not
without controversy [11–14]. One definition offered for human
CSC is that they have the ability to form tumors in immunode-
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ficient mice [15]. However, Kelly and colleagues [16] noted that
only rare human lymphoma cells meet this criterion. In contrast,
in an Em myc mouse syngeneic system, 10% or more of lymphoma
cells were tumorigenic. They suggested the apparent rarity of stem
cell-like cells of human lymphomas that form tumors in
immunodeficient mice might simply be consequence of mis-
match(es) between the human cells and the mouse microenviron-
ment. It has also been suggested that this limitation might be partly
responsible for the high Phase II attrition rate seen in oncology
trials [17,18].
An inherent assumption in many studies of both normal stem
cells and CSC is that a homogeneous population is being analyzed,
and this is depicted on lineage diagram by a single cell. However,
in the case of leukemia stem cells, the reality has become more
complex with greater heterogeneity and dependence on microen-
vironment than previously thought [19]. In reality, if normal
human hematopoietic stem cells (HSCs) from the same tissue
sample, but with different phenotypes e.g., side population (SP)
versus CD34high cells, are analyzed for production of human cells
in immunodeficient mice, differences are observed [1]. This
suggests that there is a hierarchy of functional properties expressed
by normal stem/progenitor cells. Even using different expression
levels of a specific stem cell marker to isolate normal HSC, e.g., SP,
produces cells with functional heterogeneities [20]. Whether this is
also the case for CSC has been addressed [7,8,13,21] but not fully
evaluated, although it is important because it could explain
differences in CSC properties that have been reported by different
groups who generally only employ a single isolation technique that
often differs between groups e.g., Aldefluor vs. SP cells [22,23].
Consequently, the present study was devised to determine if
breast cancer cells that met the definition of CSC, based on
expression of different specific stem cell markers, were functionally
homogeneous or heterogeneous, based not only on phenotype but
also on in vitro assays of stem cells (mammosphere formation) or
limiting cell dilution analysis of in vivo tumorigenesis. Additional
characteristics including cell growth, colony formation, expression
profiling, response to growth factor rich matrix (MatrigelTM), and
cytokine production were evaluated. To avoid the criticisms
applied to prior studies e.g., [16]; an orthotopic syngeneic murine
model that mimics the growth of human breast cancer cells in
immune intact individual, the Clone 66 model [24,25] was
employed. This model also has the advantage that it contains cells
that express various putative CSC markers (SP, CD44highC-
D24low/neg, ALDH1+, CD34high, CD133high, CD49fhigh and




Clone 66 (Cl66), a murine adenocarcinoma cell line, derived
from a spontaneously arising mammary tumor in a Balb/cfC3H
female mouse originally described by Dexter and colleagues [24],
was generously made available by Dr. James Talmadge of the
University of Nebraska Medical Center, Omaha, Nebraska. This
cell line has been described in a previous publication [25] and
grows and metastasizes in an orthotopic immune intact syngeneic
model in a manner similar to triple negative human breast cancer.
Cell Culture
A limited number of passages of parental Cl66 were maintained,
tested to be free of mycoplasma contamination, and cryopre-
served. All experiments were performed with cells at less than 20
passages after receipt. The DMEM (Dulbecco’s Modified Eagles
Medium) media (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/
ml streptomycin, 2 mM L-glutamine, 10 mM HEPES (pH 7.4),
16 MEM vitamin solution, 16 Basal Medium Eagle amino acid
solution, and 16 Modified Eagles Medium (MEM) non-essential
amino acids were used for maintaining Cl66 cells. All materials
were purchased from Gibco-BRL (Gibco-BRL, Grand Island,
New York, USA).
Animals
Female Balb/c mice, 6–8 weeks of age, were purchased from
Jackson Laboratory (Jackson Laboratory, Bar Harbor, ME, USA).
Mice were maintained in micro-isolators in the USDA (U.S.
Department of Agriculture)/AALAC (American Association of
Laboratory Animal Science) accredited facility at the University of
Nebraska Medical Center on a 12 hours light, 12 hours dark cycle.
The mice were allowed food and acidified water ad libitum.
Fluorescence Activated Cell Sorting (FACS) Analysis
Side population analysis. Side population analyses were
performed following the method described previously [23]. Briefly,
16106 cells were incubated overnight (or at least for 2 hours) at
4uC in a small volume (1.0 ml) of pre-warmed Hoechst IMDM
(Iscove’s Modified Dulbecco’s Medium). In staining media the
concentration was (1mg/ml). Adding an appropriate amount of
Hoechst 33342 dye (Sigma-Aldrich, St. Louis, MO, USA), the
specimen being stained was incubated at 37uC for 30 minutes.
After incubation, cells were kept on ice followed by flow analysis.
Antibody staining: Following enzymatic/mechanical disaggre-
gation Cl66 cell populations were filtered through a 40 mm nylon
mesh (BD Biosciences, CA, USA) to ensure single cellularity and
re-suspended in ice-cold PBS (containing 1% BSA) to a density of
106 cells/200 mL and incubated with the following antibodies: PE-
conjugated anti -CD34 (12-0341-81, 1:100), AF488- conjugated
anti -CD133 (53-1331-80, 1:100), PE- conjugated anti -CD49f (12-
0485-82, 1:100) were purchased from eBioscience (eBioscience,
San Diego, CA, USA). FITC- conjugated anti -CD44 (553133,
1:100), and PE- conjugated anti -CD24 (553262, 1:100) were
purchased from BD Biosciences (BD Biosciences, CA, USA). Cells
were analyzed using a BD FACSAria. Background signals due to
autofluorescence were eliminated using normal tissues/cells. The
remaining positive events (background) were subtracted from the
experimental samples. ALDH1 activity assay: ALDH1 activity
in cells was detected with an Aldefluor Kit, according to
manufacturer’s instructions (Stem Cell Technologies, Vancouver,
BC, Canada) followed by FACS analysis. DEAB (ALDH1
inhibitor) treated cells were used to set background and also to
correctly identify ALDH1 fluorescence. Tissue preparation: at
necropsy, tumors to be analyzed were removed, placed in sterile
medium and minced with scissors. The tissue was then transferred
to a 15 ml conical tube and repeatedly aspirated through syringes
with successively smaller sized needles until a single cell suspension
had been achieved. The cells were washed and analyzed in HPBS
(1% FBS) and stained as above. The number of positive cells was
calculated based on the assessment of fluorescence intensity
greater than that of background with tissue from normal control
animals.
Sphere Formation Assay
Sphere formation assays were performed as described previ-
ously with modifications [26]. Briefly, Single-cell suspensions were
re-suspended at a density of 1000 cells/ml in ultralow attachment
6-well or 12-well dishes (Corning Incorporated, NY, USA) in
DMEM/F-12 (Invitrogen, CA, USA) containing 5 mg/mL insulin,
Heterogeneity of Murine Breast Cancer Stem Cells
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0.5 mg/mL hydrocortisone, 25 ng/mL EGF, 25 ng/mL bFGF,
Heparin 4 mg/mL (0.5 U/mL), 1% BSA and Gentamycin sulfate
(Gibco-BRL, NY, USA). Cultures were fed weekly and tumor
sphere formation was monitored each week. Tumor spheres were
disaggregated periodically by 5 min Accutase treatment (Stem Cell
Technologies, Canada) followed by mechanical disaggregation
with a sterile Pasteur pipette. Phase-contrast images were obtained
under 406 magnification to visualize the morphology of sphere,
and all spheres were counted, plotted and presented as histogram.
Each experiment was performed in triplicate. More than two
independent experiments were performed.
Assay for Anchorage Independent Growth in Soft Agar
Anchorage-independent growth assays were performed as
described previously with reduced cell numbers [27]. Briefly,
56102 cells of various populations without or with stem
phenotypes were plated in 6-well plates in 1.5 mL of 0.35%
agarose (Sigma-Aldrich, MO, USA) in DMEM media on top of a
bottom layer of 0.5% agarose in DMEM media. Plates were
incubated for 2 weeks. Phase-contrast images were obtained under
1006magnification to visualize the morphology of agar colonies,
and colonies were counted, plotted and presented as histogram.
Each experiment was performed in triplicate. At least two
independent experiments were performed.
Growth Kinetic Studies
Various sorted cells were cultured overnight to allow cells to
recover from the stress of sorting. Growth kinetics and population
doubling time of various cell populations with or without stem
phenotype were determined as described previously [28]. Briefly,
for growth curves, cells were seeded at 16104 cells/well in 6-well-
plate in triplicate. Viable cells of different populations in each well
of the 6-well plates were counted for 7 days by a viable cell counter
(ViCell Coulter counter, Beckman Coulter, Inc., CA, USA).
Population doubling times of various cell populations with or
without stem phenotype were calculated from the number of cells
growing in the log phase (96–144 h) and using the formula:
Td = 0.693 t/ln (Nt/N0), where t was time (in hour), Nt was the cell
number at time t, and N0 was the cell number at the initial time.
Colony Forming Assays
Colony forming assays were performed as described earlier [29].
Briefly, the colony-forming efficiency of various cell populations
with or without stem phenotypes was examined 14 days after
plating 250 cells plated in quadruplicate, by staining with crystal
violet (Sigma-Aldrich, MO, USA). Colonies of .50 mm in size
were counted using quantity One software (Bio-Rad, Richmond,
CA, USA). Results are presented as an average of 3 independent
experiments.
In vivo Tumorigenesis in Syngeneic Balb/c Mice
Cell populations without or with stem cell phenotypes were
harvested using 0.05% trypsin-EDTA (Gibco BRL, NY, USA)
washed twice and suspended in HBSS (Gibco BRL, NY, USA),
without serum, immediately prior to mixing with MatrigelTM (BD
Biosciences, San Jose, CA, USA). The cells were adjusted to
deliver the desired number of cells in a total volume of 0.05 ml
with 1:1 dilution of MatrigelTM. The cell suspensions were injected
into an intact inguinal mammary fat pad. In first set of
experiments, 6000, 3000, 1000 cells were transplanted in triplicate
into mammary fat pads. Tumors generated from each group (of
6000, 3000, and 1000 cells) were dissociated into single cell
suspensions, analyzed for stem cell phenotypes, cultured for two
weeks and re-transplanted using 1000 cells of the pooled
population of each group. In second set of experiments, 1000,
500, 200 cells were transplanted into mammary fat pads. Again,
tumors generated from each group of 1000, 500, and 200 cells
were dissociated into single cell suspensions, cultured for two
weeks and re-transplanted using 500 cells of the pooled population
of each group. In a third set of experiments, 50, and 25 SP cells
were transplanted into mouse mammary fat pads. Initially, low
numbers of tumors without major differences in tumorigenic
potential of ALDH1+ and ALDH12 cells were observed.
Consequently, 24000, 10000, and 6000, cells of ALDH1+ and
ALDH12 cells were transplanted, in triplicate, into mammary fat
pads of mice. Mice were monitored on alternate days for the
development of tumors at the injection site and the frequencies of
tumor noted. The tumor size was measured (W6H6L) and the
volumes were calculated.
Ethics Statement
All experiments were carried out in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of Nebraska Medical Center,
Omaha, Nebraska (Permit Number: 11-004-07-FC). All trans-
plantations were performed under isoflurane anesthesia. Finally,
mice were euthanized according to IACUC (Institutional Animal
Care and Use Committee) guidelines and excised tumors were
subjected to histological analyses.
Histology
Tumors recovered, at necropsy, were fixed in 10% buffered
formalin and processed to prepare routine procedures for paraffin
sections. Briefly, following fixation, the tissue was dehydrated using
a graded series of alcohol baths beginning with 50% and
progressing to100%. The tissue was then cleared with xylene,
infiltrated and embedded in paraffin. Five micron tissue sections
were cut using a Leica rotary microtome and stained with
hematoxylin and eosin for morphological analysis. Hematoxylin
and eosin (H&E) staining: H&E staining was performed
following the methods described previously [30]. Slides were
deparaffinized, rehydrated and stained with Harris hematoxylin
and eosinY solutions (Surgipath, Richmond, IL, USA). After
staining, the sections were dehydrated and coverslipped using
Limonene Mount (Sigma-Aldrich, MO, USA). All histological
material was examined and photographed using a Neurolucida
virtual microscopy scanning system (MBF Bioscience, VT, USA)
attached to Zeiss Axioskop2. The tumor types were characterized
and evaluated for hypoxic areas, blood vessel densities (BVD), and
evidence of secretory product.
Cytokine Assays
Unsorted Cl66 cells at a density of 105 per 6 cm dish were
grown in culture with or without MS-5 stromal cells and
supernatants were harvested on day 3. Supernatants were
centrifuged at 14,0006g for 5 minutes, and transferred into a
clean test tube. Protein concentrations were determined using a
BIO-RADD/C (Bio-Rad, Richmond, CA, USA) protein estima-
tion kit. Levels of a wide range of inflammatory/angiogenic
cytokines and chemokines were measured using a mouse Proteome
Profiler Array (R&D Systems, MN, USA) following the manufac-
turer’s procedure. Briefly, 50 mL of cell culture supernatants were
prepared for addition to antibody pre-spotted nitrocellulose strips.
Antibodies were spotted in duplicate on each nitrocellulose strip.
After binding the complementary cytokine/chemokine during an
Heterogeneity of Murine Breast Cancer Stem Cells
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overnight incubation, strips were treated with streptavidin-HRP
containing buffer, followed by treatment with chemiluminescent
reagent. The enhanced chemiluminescence signals were recorded
using a light-sensitive film (GeneMate Blue Lite Autorad Film,
BioExpress, Kaysville, UT, USA), which was scanned to
determine the relative intensity matrix. Pixel density associated
with the chemiluminescent signal measured was converted to
intensity 0 to +4. The average value for each cytokine, after
subtracting background values, was graphed as histograms that
allowed comparison of cytokine production under various
experimental conditions.
Statistical Analyses
Data were analyzed using two-tailed Student’s t-tests in Excel
and two-tailed Fisher’s exact tests where appropriate, using
Microsoft Excel 2010. P,0.05 was considered statistically
significant. Flowjo V4 (Tree Star, Inc., Ashland, OR, USA) was
used for FACS data analysis.
Results
Cl66 Murine Breast Cancer Cells Comprised Distinct Cell
Subpopulations with or without Stem Cell Phenotypes
We employed Cl66 cells as this is an orthotopic model that
grows in mammary fat pad and metastasizes in immune intact
mice [25]. This model replicates the growth and metastasis of
human breast cancer. In a preliminary screening of breast cancer
cell populations, isolated using FACS sorting from Cl66, we
observed the presence of varying proportions of SP, CD44highC-
D24low/neg, ALDH1+, CD34high, CD133high, and CD49f high cells
(Table 1, Figure 1). There was about a 3000 fold variation in the
proportion of cell populations with ‘‘stem cell’’ phenotypes
(Table 1). A cell population with CD44highCD24low/neg phenotype
was present at 0.03% 60.01% in Cl66 and it was challenging to
isolate sufficient cells for functional studies. CD133high cells were
also present in Cl66 cells but the flow profile of these cells
indicated that adequate separation by sorting would be challeng-
ing. Consequently, cells with this phenotype were excluded from
this study. From the results presented in Table 1, we concluded
that Cl66 murine breast cancer cells expressing various stem
phenotypes were likely heterogeneous based on phenotypes. This
prompted questions as to potential heterogeneities of their
functional properties. We performed additional experiments in
order to test this hypothesis. In the interest of brevity only the most
informative data are presented.
Various Cell Populations with Stem Phenotypes
Generated Tumor Spheres at High Efficiency
The use of the mammosphere assay to evaluate the presence of
stem cells in a population of mammary epithelial cells (MECs) was
previously validated by the capacity of a single murine mammo-
sphere to regenerate an entire mammary ductal tree when
transplanted into a cleared mouse mammary stromal fat pad
[31]. Here, we sought to detect the frequency of sphere formation
among various cell populations with or without stem phenotypes
such as, SP or non-SP, ALDH1+ or ALDH12, CD34high or
CD34low, and CD49fhigh or CD49flow/neg cells. These various cell
populations with or without stem phenotypes were analyzed for
tumor sphere formation [26,32–37] in serum free medium
supplemented with bFGF and EGF. Cells with stem phenotypes
quickly developed tumor spheres, while we observed low sphere
formation when the cell populations with non-stem phenotype
were grown under the same culture conditions (Figure S1). Cells
with the SP phenotype showed formation of larger spheres than
cells with other phenotypes. Sphere forming efficiency of SP and
ALDH1+ phenotype was 4–5% whereas sphere forming efficiency
of CD34high and CD49fhigh was 2–4% (Figure 2). Addition of
MatrigelTM (a source of growth factors?) increased the size of
spheres with SP, ALDH1+, CD34high, and CD49fhigh when
compared with their respective non-stem cell populations. The
only exception was CD49flow/neg cell population (a purported non-
stem phenotype), which formed more spheres than the CD49fhigh
cell population, suggesting that this phenotype does not select for
sphere forming cells. Secondary sphere formation was observed
only with SP, CD34high, CD49fhigh and CD49flow cells (data not
shown). Very limited or no secondary sphere formation was
observed with ALDH1+, ALDH12 and non-SP cells. Secondary
sphere formation was much higher with SP than CD34high cells.
This indicated differential self-renewal of sphere forming cells with
a SP phenotype under in vitro conditions. Consistent with the
primary sphere formation, CD49fhigh and CD49flow cells formed
secondary spheres in significant numbers. Overall, these data
indicate that sphere formation by ALDH1+, SP, CD34high, and
CD49fhigh cell populations was heterogeneous, suggesting differ-
ences in self-renewal.
Cell Populations with Stem Phenotypes Exhibited
Reduced Proliferation, Lower Colony Formation and
Enhanced Agar Colony Formation
Proliferation, a major property of cancer cell populations, is
mostly exhibited by progenitor and transit amplifying cells,
whereas stem cell populations are postulated to exhibit quiescence;
so we sought to investigate the proliferation of various cell
populations with or without stem cell phenotypes. Proliferation
analysis indicated that the proliferation rate was much higher in
ALDH1+, non-SP, CD34low, and CD49fhigh than their respective
counterparts (Figure 3A). Population doubling times of ALDH1+,
and CD49fhigh (17 hours, and 20 hours) was less (p = 0.0004,
p = 0.01) than ALDH12, and CD49flow (21 hours, and 24 hours).
The population doubling time of CD34high cells (25 hours) was
higher (p = 0.0001) than CD34low (20 hours). This data correlated
well with the proliferation data. Although the growth of SP cells
was much lower than that of the non-SP population, cell death
associated with the non-SP population made it challenging to
determine actual population doubling times. Potentially, the
clastogenic effects of the Hoechst dye, which unlike SP cells, was
not excluded from non-SP cells, might have contributed to cell
death in this population. MatrigelTM favored the proliferation of
the CD49flow/neg population (Figure 3A). These results suggested
that SP, CD34high, and CD49flow/neg have higher frequencies of
stem cell populations. Although ALDH12 cells showed less
proliferation and thereby might have higher frequencies of stem
cell populations, this finding is not supported by the published
literature [22] and might need further investigation. When we
analyzed colony formation efficiencies, cell populations with
ALDH12, non-SP, and CD34high phenotypes showed higher
(p = 0.002, 0.0006, 0.005) colony forming efficiency than their
respective stem cell phenotype positive counterparts (Figure 3B).
The CD49fhigh and CD49flow/neg cells did not show major
differences in colony forming efficiencies (p.0.05) suggesting that
this phenotype might not be a suitable phenotype to differentiate
stem and non-stem cell populations under in in vitro culture
conditions. MatrigelTM increased colony formation only for the
CD34low population. These results suggest that ALDH12, non-SP,
CD34high, and CD49fhigh cells have a greater proportion of
progenitor cells than their stem cell phenotype counterparts.
Almost all cell populations with stem or non-stem phenotype
formed agar colonies (Figure S2) without or with MatrigelTM.
Heterogeneity of Murine Breast Cancer Stem Cells
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Calculated total colonies were found to vary in numbers (Figure 4).
Cell populations with stem cell phenotypes formed higher
numbers of agar colonies than cell populations with non-stem
phenotypes. ALDH1+ and ALDH12 formed more agar colonies
than SP cells and SP cells formed more agar colonies than non-SP
cells (Figure 4). Soft agar colony formation was much lower in
CD34high and CD49fhigh cell populations. MatrigelTM increased
the size of agar colonies of all cell populations, indicating that all
cell populations responded to the matrix or growth factors present
in MatrigelTM. The agar colony formation data suggested that the
oncogenic phenotype is more highly represented in ALDH1+, SP,
and CD34high cells than their non-stem cell counterparts. CD49f
Figure 1. Expression of putative stem cell markers in Clone 66 murine breast cancer cells. (A) After staining Cl66 cells with Hoechst 33342
dye followed by FACS analysis, we detected 1.23% 60.95% cells were SP cells (n = 3). (B) When Cl66 cells were FACS analyzed after Aldefluor
treatment with or without DEAB (ALDH1 inhibitor), we found approximately 4.16% 63.26% (n = 3) cells were ALDH1+. (C) After staining with anti-
CD34 antibody followed by FACS analysis, we identified 90% 613%, n = 4 cells were positive for CD34. Cells expressed highest levels of CD34
(CD34high) and lowest levels of CD34 (CD34low) were selected and sorted for this study. (D) After staining with anti-CD49f antibody followed by FACS
analysis, we identified 99.47% 60.21% (n = 3) cells were positive for CD49f. Cells with the highest levels of CD34 expression (CD34high) and lowest
levels of CD34 expression (CD34low) were selected and sorted for this study. For the SP analysis, an X-cite LightWave air-cooled 20 mW UV laser at
354 nm (made by JDS Uniphase) was used. For the ALDH1, PE, FITC and Alexa488 analysis, a Saphire air-cooled 100 mW blue laser at 488 nm (made
by Coherent) was used. Average data from more than two independent assays are shown. n = number(s) of assay(s) performed.
doi:10.1371/journal.pone.0078725.g001
Heterogeneity of Murine Breast Cancer Stem Cells
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low/neg cells showed more agar colony formation (or oncogenic
potential) than CD49fhigh suggesting that this phenotype is
inadequate for distinguishing stem versus non-stem phenotype.
Indeed, CD49f low/neg cells might be more oncogenic and enriched
with stem cells, but this needs further confirmation. Consequently,
cells with this phenotype were not evaluated further. The
differences of functions of these cell populations might be an
outcome of transcriptional changes or post-translational (micro-
RNA) differences between the cell populations with a stem cell
phenotype, as observed in other systems [38,39] and might reflect
soluble factor production [40]. This possibly requires further
evaluation.
Cell Populations with Stem Phenotypes have a Higher
in vivo Tumorigenic Potential
After performing in vitro functional studies, without and with
MatrigelTM, we sought to investigate the tumorigenic potential of
isolated cell populations with or without stem phenotypes using
mammary fat pad transplantation that provides a suitable stromal
microenvironment for tumor growth. Based on the results of the
in vitro sphere forming assays, which indicated that the SP and
ALDH1+ possessed stem cell activities and non-SP and ALDH12
cells were less potent and given that both CD49fhigh and CD49flow
cells had similar sphere forming activities; and CD34high and
CD34low cells had less sphere and agar colony forming activities
than SP and ALDH1 phenotypes, the focus of the in vivo
tumorigenic assays emphasized a comparison of SP to non-SP
cells and ALDH1+, and ALDH12 cells.
Various cell populations with or without stem phenotypes were
transplanted at limiting cell dilutions (24000, 10000, 6000, 3000,
1000, 500, 200, 50, or 25 cells/fat pad) with 1:1 MatrigelTM
orthotopically into multiple mouse mammary fat pads of two
groups of female Balb/c mice (n = 3). SP cells (1000, 3000, and
6000 cells) produced detectable tumors at week 3, while tumors
resulting from non-SP cells (#3000 cells) were detectable only
after 5 weeks (Figure 5A). However, 6000 cells of SP and non-SP
produced almost similar tumor formation at week 2–3 indicating
quantitative rather than qualitative differences in tumorigeneicity.
Results indicated that fewer SP cells (,100 cells/fat pad) were
needed to form tumors than ALDH1+ cells (.1000 cells/fat pad)
suggesting heterogeneities in tumorigenesis (Table 2). Further,
ALDH1+ and ALDH12 did not show consistent differences in
tumor formation (Figure 5B; Table 2), which suggests that
ALDH1+ and ALDH12 cell populations might have lower
frequencies of stem-type cells or differed in factor(s) production.
Cell populations with an SP phenotype but not with non-stem
phenotype (non-SP) formed tumors in all mice receiving 200 or
more cells suggesting a higher frequency of stem type cells in the
SP population. When compared, volumes of tumor formed from
6000 cells of SP, non-SP, ALDH1+ and ALDH12 cells, showed SP
tumors grew fastest (Figure 5C). Consequently, it might be possible
that the environment of the mammary fat pad favors enhanced
proliferation of SP cells when compared with non-SP, ALDH1+
and ALDH12 cells.
In addition to tumor growth, the morphology of the tumors
was evaluated. Initially, the characteristics of 24 tumors i.e., an
average of 6 from each group were evaluated in a blinded
fashion on hematoxylin and eosin stained mid-plane of stained
Table 1. Various cell populations (%) with stem cell phenotypes were evaluated in Clone 66.
References Tumor type
Putative stem cell markers used
for sorting
Average cell populations (%) present in
Clone 66 in this study
[54] Acute myeloid leukemia CD34high 90%613%, n = 4
[57] Brain cancer CD133high 0.3260.28%, n = 2
[5] Breast cancer CD44highCD24low/neg 0.03%60.01%, n = 2
[23] Breast cancer SP 1.23%60.95%, n = 3
[22] Breast cancer ALDH1+ 4.16%63.26%, n = 3
[58] Breast cancer CD49fhigh 99.47%60.21%, n = 3
doi:10.1371/journal.pone.0078725.t001
Figure 2. Evaluation of self-renewing cells in sorted cell
populations of Cl66 murine breast cancer cells. Tumor spheres
were obtained by culturing sorted cells from Cl66 murine breast cancer
cells in tumor sphere medium containing EGF and bFGF. Cells were
plated at a density of 1000 cells/ml. Percent sphere formation was
calculated and plotted against stem or non-stem phenotype with (+M)
or without MatrigelTM. Cell population with the SP phenotype showed
formation of larger spheres than cells with other phenotypes. Sphere
forming efficiency of SP and ALDH1+ phenotype was higher (4–5%)
than CD34high and CD49fhigh, which were 2–4%. Formation of spheres
was observed from cell populations with stem and non-stem cell
phenotypes. The only exception was cell population with CD49flow/neg
phenotype (a purported non-stem phenotype), which formed more
spheres than the CD49fhigh cell population. Addition of MatrigelTM
increased the numbers of spheres of cell populations with stem and
non-stem cell phenotypes. Data are the average of two independent
experiments.
doi:10.1371/journal.pone.0078725.g002
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sections of each tumor by three investigators. The mid-tumor
sections were characterized as to area and extent of central
necrosis. All tumors were undifferentiated adenocarcinomas
(Figure 6A). The tumors fell into two broad categories: large
size (.3 mm in diameter) with metaphases and central necrosis,
moderate to high blood vessel densities (Figure 6B) i.e., about
seven or greater blood vessels per high power field (4006) with
moderate diffuse inflammatory/immune cell infiltrates and with
limited protein secretion vesicles, versus smaller (,3 mm in
diameter) tumors with minimal necrosis, lower blood vessel
densities i.e., about four or fewer blood vessels per high power
field (4006), with moderate to high content of secretory vesicles,
without significance evidence of inflammatory/immune cell
infiltrates. Note that microvessels have been reported to predict
metastatic status in breast cancer [41]. Since this is a syngeneic
model, the stimulus for accumulation of inflammatory/immune
cells was unclear, unless release of molecular components of
apoptotic cells was a factor. Multiple elongated/spindle cells
Figure 3. Cell populations with stem phenotypes exhibited reduced proliferation and lower colony formation. (A) In proliferation
analyses, when the number of cells was plotted against the incubation period (days), the proliferation rate was much higher in ALDH1+, non-SP (non-
side population), CD34low, and CD49fhigh than their respective counterparts. MatrigelTM only favored the proliferation of the CD49flow/neg population.
Population doubling times of ALDH1+and CD49fhigh cells (1760.2, 2060.4 hours) was less than ALDH12 and CD49flow cells (2160.26, 2460.41 hours)
when calculated from the number of cells growing in log phase (day 2 to 6) using the formula, Td
= 0.693 t/ln (Nt/N0). CD34
high showed higher
(2560.43 hours) population doubling time than CD34low (2060.33 hours). With MatrigelTM indicated by +M. (B) When analyzed for colony formation
efficiencies, cell populations with ALDH12, non-SP, CD34high, CD49fhigh phenotypes showed higher colony forming efficiency than their respective
counterparts. The CD49fhigh and CD49flow/neg cells did not show major differences in colony forming efficiencies, suggesting that this phenotype
might not be a suitable phenotype to differentiate stem and non-stem phenotype, at least under in vitro culture conditions. MatrigelTM increased
colony formation only for the CD34low population. With MatrigelTM indicated by +M.
doi:10.1371/journal.pone.0078725.g003
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were evident in different extents and at various sites of many
tumor sections. Morphologically these resembled myoepithelial
cells but could be cells in hypoxic areas of the tumors that were
attempting to access oxygen from adjacent blood vessels or
exhibiting epithelial to mesenchymal transition. The co-relation
of morphological characterization of tumors e.g., blood vessel
density with factor production requires further investigation.
At this point, the blinding code was broken. The former group
of larger tumors was generated by SP and non-SP cells (Figure 6A
top panel). The primary difference between these two types of
tumor was blood vessels densities, which surprisingly (based on
growth rates), were higher in non-SP versus SP tumors. Cells in
metaphase were more evident in SP (3.061.5) than non-SP
(0.760.5) tumors, and these data correlated with the growth of
tumors. The second group of smaller tumors was generated by
ALDH1+ and ALDH12 cells (Figure 6A bottom panel). The only
differences between ALDH1+ and ALDH12 was observed in
blood vessel densities and numbers of secretion vesicles with
proteinaceous product. ALDH1+ tumors exhibited fewer blood
vessels and secretion vesicles than ALDH12 tumors. These data
demonstrated that not only does the number of cells required to
form tumors differ between breast cancer cells with or without
stem phenotypes, but also the size, relative to time of growth and
morphology of the tumors differed between SP, non SP versus
ALDH1+, ALDH12 tumors. Cells in metaphase were more
evident in ALDH1+ (1.360.5) than ALDH12 (0.760.5) cells.
These data indicate that in vitro heterogeneities evident in Cl66
murine breast cancer cells, with or without stem cell phenotypes,
extended to the morphologies of tumors that these cells generated
in vivo.
Demonstration of in vivo Self-renewal by Re-
transplantation of Cells from Primary SP, Non SP, ALDH1+
and ALDH12 Tumors
An in vivo re-transplantation assay within an initial set of
experiments was performed. Pooled populations of 1000 cells
and with 200 cells in a second set of experiments of primary
tumor cells derived from SP and non-SP cells showed similar
growth characteristics and similar sized tumors. However, a re-
transplantation assay with pooled cells of primary tumors
formed by ALDH1+ and ALDH12 cells did not produce
significant tumor growth (data not shown). Analysis of tumors
formed by purified SP cells i.e. initially 100% SP cells, showed a
rapid loss of the majority of cells with the SP phenotype and at
necropsy after 3 weeks, these tumors only had the SP cell
content of unsorted cells (0.06%). In contrast, tumors formed
initially from 100% non-SP cells, i.e. 0% SP cells, acquired a
significant content of SP cells (0.29%) by the time of necropsy
Figure 4. Cell populations with stem phenotypes exhibited
enhanced agar-colony formation. Agar colonies were obtained by
culture of sorted cells from mouse mammary carcinoma Cl66 cells
cultured in soft-agar containing complete DMEM media. Stem-type cells
formed higher numbers of agar colonies than non-stem type cells.
ALDH1+ and ALDH12 formed more agar colonies than SP cells and SP
cells formed more agar colonies than non-SP cells. Soft agar colony
formation was much lower in CD34high and CD49fhigh cell populations.
MatrigelTM increased the size of agar colonies of all cell populations,
indicating that all cell populations responded to the growth factors
present in MatrigelTM. With MatrigelTM indicated by +M. All data
presented are the average of 2 independent experiments.
doi:10.1371/journal.pone.0078725.g004
Table 2. Formation of tumors by cell populations with stem/non-stem cell phenotypes.
Cell phenotypes
# of cells transplanted to 3
or 4 separate fat pads/mouse
% mice with
tumor Cell phenotypes
# of cells transplanted to 3
or 4 separate fat pads/mouse
% mice with
tumor
SP 6000 100 ALDH1+ 24000 50
SP 3000 100 ALDH1+ 10000 50
SP 1000 100 ALDH1+ 6000 33
SP 500 100 ALDH1+ 3000 0
SP 200 100 ALDH1+ 1000 0
SP 50 67
SP 25 0
Non-SP 6000 100 ALDH12 24000 50
Non-SP 3000 100 ALDH12 10000 25
Non-SP 1000 100 ALDH12 6000 25
Non-SP 500 100 ALDH12 3000 33
Non-SP 200 0 ALDH12 1000 0
doi:10.1371/journal.pone.0078725.t002
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at the 3rd week. This indicated that the SP phenotype was
pliable in vivo and was influenced by currently undefined factors.
Other studies have shown that the stem cell versus non-stem
cell content of tumors can be influenced by IL6 secretion [42]
and increased by hypoxia [43]. These are candidate mecha-
nisms, that could be involved both at the time of the initial
injection of the cells into the mammary fat pad (and could
depend on the number of cells injected) and/or subsequently,
on areas of necrosis within the growing tumors which might
increase as tumor size increases or be influenced by blood vessel
densities at the site of the tumor. These important issues require
additional analyses.
When we analyzed the H & E stained tumor sections
(Figure 6C), of pooled SP cell generated tumors, we noted they
exhibited more blood vessels than the original SP cells. However,
pooled non-SP generated tumors showed fewer blood vessels than
the original non-SP cell tumors. In addition, the pooled SP tumors
had a lower content of SP cells compared to the pooled non-SP
tumors. This implicates the tumor cell types in the stimulation of
blood vessel formation which, in turn, prompted an evaluation of
the soluble factors produced by these tumor cells. In addition, or
alternatively, these data suggested that there might be a differential
response to hypoxia by SP versus non-SP cells, with SP cells being
more resistant to the effects of hypoxia.
Increased Levels and Numbers of Cytokines/Chemokines
were Produced during Interaction of Clone 66 with MS-5
A role for cytokines/chemokines in growth and metastasis of
breast cancer [42,44] and other cancers [45–47] has been
described. We observed characteristic differences in tumors
generated from SP, non-SP, ALDH1+ and ALDH12 cells
transplanted to the mammary fat pad of syngeneic Balb/c mice
and the pliability of these phenotypes in vivo. Differences in blood
vessel densities were observed. Moreover, SP and non-SP tumors
showed a variable presence of inflammatory/immune cells that
suggested factor production by these two populations might
differentially attract inflammatory/immune cell populations. In
addition, we also observed that fewer SP cells were needed to form
tumors than ALDH1+ cells, also suggesting either the presence of
more cells with stem phenotypes in SP populations or heteroge-
neities related to the levels of factors/cytokines/chemokines
produced by the differing cell populations, which could promote
tumor cell growth in the microenvironment. As the in vitro sphere
forming capacity of SP and ALDH1+ cells was found to be the
same (4–5%), we investigated the production of cytokines/
Figure 5. SP cell populations with stem phenotypes have higher tumorigenic potentials. Various cell populations with stem phenotypes
were transplanted orthotopically at different dilutions (24000, 10000, 6000, 3000, 1000, 500, 200, 50, or 25 cells/fat pad) with 1:1 MatrigelTM into
mouse mammary fat pads. Tumor volumes were calculated every alternate day for 6 weeks. When tumor growth was below 10 mm3, mice were
necropsied following guideline and tumors were excised and analyzed. (A) Results indicated that fewer SP cells were needed to form tumors than
ALDH1+cells, suggesting heterogeneities in tumorigenicity. A characteristic that might be related to these heterogeneities was levels of cytokines/
chemokines produced by the differing cell populations. (B) ALDH1+ and ALDH12 did not show consistent differences in tumor formation. (C)
Volumes of tumors formed from 6000 cells of SP, non-SP, ALDH1+ and ALDH12 cell populations showed that SP grew faster than non-SP, ALDH1+ and
ALDH12 cells.
doi:10.1371/journal.pone.0078725.g005
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Figure 6. Histological analyses of tumors generated in mammary fat pads of Balb/c mice. Tumors were generated from SP, non-SP,
ALDH1+, or ALDH12 cells transplanted orthotopically in mammary fat pads of Balb/c mice. (A top panel) H & E stained tumor sections generated
Heterogeneity of Murine Breast Cancer Stem Cells
PLOS ONE | www.plosone.org 10 November 2013 | Volume 8 | Issue 11 | e78725
chemokines by these cells without and with the presence of
mesenchymal stromal cells. The intrinsic production of cytokines
by Cl66 was limited to eight molecules (Figure 7A). Of these,
RANTES was highest, with IP-10, TIMP, and KC intermediate
high, followed by mid-level JE, MIP-2; and low levels of IFN-c, M-
CSF (Figure 7A). Co-culture of Cl66 with stromal MS-5 increased
the levels of multiple chemokines/cytokines (Figure 7A) and the
production of other chemokines/cytokines (Figure 7B) indicating
that one consequence of the interaction of Cl66 murine breast
cancer cells with stromal MS-5 cells was an increase in cytokine
production. Note, in these co-culture experiments, that the source
(tumor cells or stromal cells) of these chemokines/cytokines was
not defined in this study. Overall, RANTES was high in both Cl66
cells alone and in association with stromal cells. IP-10, KC and JE
levels were also highly elevated in association with stromal cells.
Attempts to evaluate cytokine production by sorted stem cell
populations were challenging because these populations are rare,
and it proved to be difficult to obtain sufficient levels of protein for
reliable assay. Although cell numbers could be amplified by
growth in culture, these cells progressively lost their stem cell
phenotype with time and thus reverted to the composition of
unsorted cells.
Discussion
Various investigators have isolated CSCs, which are proposed
to be therapy resistant [48,49] and responsible for relapse of the
tumor following remission after therapy [50] as well as metastases
[51–53], employing different phenotypes including side population
(SP), CD44highCD24low/neg, ALDH1+, CD34high, CD133high, and
CD49fhigh in either murine or human breast cancers [5,22,23,54–
58]. The majority of these different populations have not
previously been directly compared for functions. However, when
comparisons of the functions of such cells were undertaken in this
study, using Cl66 murine breast cancer cells, we observed that
breast cancer cells with various stem cell phenotypes were present
in various proportions in the same cell population. This
comparison itself indicated that the stem cell compartment was
likely heterogeneous. However, overlap was difficult to address
directly in an analysis of multiple stem cell phenotypes, because of
challenges associated with spectral overlaps of the fluorescent
markers e.g., SP and ALDH1+. However, based on differing
numbers of such cells in any population of cells, it is very possible
that they represent functionally different, although potentially
overlapping, cell populations. This question was addressed in these
studies.
Prior studies have demonstrated that the ability of breast cancer
cells to form mammospheres in vitro, especially, secondary and
tertiary mammospheres, depends on the presence of self-renewing,
gland-reconstituting cells with a stem phenotype within the
population [31,36]. Further, the use of mammosphere assays to
assess the presence of stem cells in a population of mammary
epithelial cells (MECs) has been further validated by the fact that a
single murine mammosphere can regenerate an entire mammary
ductal tree when transplanted into a cleared mouse mammary
stromal fat pad [31]. We observed that cells with stem phenotypes
formed more spheres than non-stem type cells. Our results showed
that SP cells formed more and bigger spheres than other cells with
stem phenotypes; and this suggested that the SP cell population
contained a greater number of cells with stem cell characteristics.
When we analyzed the formation of secondary spheres, we
observed no sphere formation by non-SP, ALDH1+ and
ALDH12, CD34low populations. In contrast, we observed sphere
formation with SP, CD34high CD49fhigh, and CD49flow/neg
suggesting self-renewing cells in SP, CD49f, and CD34high
populations. The formation of secondary spheres in both
CD49fhigh, and CD49flow/neg populations indicated that this
phenotype was not a good stem versus non-stem cell distinguishing
marker.
Based, in part, on normal tissue systems, colony forming
efficiency is likely a marker of more differentiated, progenitor cells
than stem cells [59]. We observed that the colony forming
efficiency was higher (.40%) from ALDH1+ cells than SP cells
(,40%), which suggested that ALDH1+ might represent an
enriched progenitor cell population. This would correspond also to
their lower ability to generate secondary and tertiary spheres.
Further, anchorage–independent growth is a trait commonly used
to determine the oncogenicity of cells in vitro [60]. Obvious
increases in soft agar large colony formation were observed with
cells with stem phenotypes compared to non-stem type cells with
the exception of CD49fpos cells. Greater numbers of soft agar
colony formation by ALDH1+ cells than SP cells might also
suggest the quiescence nature of SP cells. The differences in SP
and non-SP phenotypes might be associated with gene transcrip-
tion expression or epigenetic differences that may play important
role(s) in determining stem cell phenotypes [61].
The coordinated interactions of epithelial cells with their stroma
is fundamental to controlling their growth and differentiation in
normal and pathological situations [62]. We therefore, sought to
identify cell populations with or without stem phenotypes that had
the highest tumorigenic potential in the stromal environment of
the mammary fat pad by in vivo orthotopic tumor formation in
syngeneic recipients. When we investigated in vivo tumor forma-
tion by orthotopically transplanting cell populations with or
without stem phenotypes into mouse mammary fat pads, we
observed that fewer cells with a stem cell phenotype were needed
for tumor formation than ‘‘non-stem’’ cells. Further, the SP
population was the most tumorigenic as it produced tumors when
as few as 50 cells but not when only 25 cells were transplanted.
However, when large enough numbers (e.g. 6000 cells) of cells with
stem cell phenotypes (SP) as well as non-stem cell phenotypes (non-
SP) were transplanted, they also formed tumors, suggesting
quantitative rather than qualitative differences in tumorigenicity.
Also fewer SP cells were needed to form tumors than ALDH1+
from SP and non-SP cells demonstrated the presence of blood vessels, inflammatory/immune cells with heterochromatic nuclei, and cells with
secretion vesicles. Metaphase cells were only evident in SP tumor sections. (A bottom panel) H & E stained tumor sections generated from ALDH1+
and ALDH12 demonstrated the presence of blood vessels, inflammatory/immune cells with heterochromatic nuclei, and cells with secretion vesicles.
Metaphase cells were evident in ALDH12 tumor sections. (B) non-SP cell derived tumors showed higher numbers of blood vessels (approx. 13) than
SP cell derived tumors (approx. 3) and ALDH12 cell derived tumors exhibited more (approx. 7) blood vessels than ALDH1+ derived tumors. (approx.
4). (C) Histological analyses of tumor sections generated from orthotopically re-transplanted pooled populations of SP, and non-SP derived tumor
cells. Sections demonstrated the presence of blood vessels, inflammatory/immune cells with heterochromatic nuclei and secretion vesicles however,
sections of re-transplanted pooled SP population derived tumor cells exhibited more blood vessels ($3) than purified SP population derived tumors
(#3) and re-transplanted pooled non-SP population tumors exhibited fewer blood vessels (5–6) than purified non-SP population derived tumors (9–
13). Cells in metaphase were only observed in re-transplanted pooled SP cell derived tumors. Original magnification, 4006. * = blood vessels; I/
I = Inflammatory/immune cells with heterochromatic nuclei; SV = secretion vesicles; M = Cell in metaphase.
doi:10.1371/journal.pone.0078725.g006
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cells confirming the conclusions of the in vitro studies that the SP
population has a greater content of cells of a self-renewing
tumorigenic stem cell phenotype than ALDH1+ cells that appear
to have properties expected of more differentiated stem or
progenitor cells. Comparisons of in vivo tumor growth showed
that tumors formed by SP cells grew faster than non-SP, ALDH1+
and ALDH12 cells. Re-transplantation of pooled populations of
SP and non-SP cells suggested that the non-SP cell population in
mammary fat pad induced more blood vessels than SP cell tumors.
When we analyzed non-SP tumors using FACS analysis, we
observed that the number of SP cells increased sharply with time
from 0% to 0.29% within non-SP tumors. In contrast, SP tumors
showed a decrease of the SP population from 100% to 0.06%
suggesting that two populations appear to maintain equilibrium
i.e., in vitro 100% SP cells eventually generated the same
proportion of SP versus non-SP cells present in unsorted cells.
Speculatively, tumor hypoxia may regulate this equilibrium, but
this remains to be evaluated.
Earlier studies suggested that cells with CD44highCD24low/neg
phenotype were more metastatic than non- CD44highCD24low/neg
cancer cells [51–53]. In this study, we have not evaluated
metastasis of various cell populations with stem phenotypes due
to the challenges associated with the detection of metastases when
mice are transplanted minimum numbers of cells (e.g., 50) and the
size of the primary tumors is restricted by animal welfare concerns.
This warrants future study.
Histopathologically, it was evident that ALDH1+ and ALDH12
cells had similar inflammatory/immune cell infiltration and
necrosis however; a difference was that ALDH1+ tumors exhibited
fewer blood vessels, and secretion vesicles with proteinaceous
product than ALDH12 tumors. SP and non-SP tumors were
similar as regards to the inflammatory/immune cell and central
necrosis. However; blood vessels and the presence of vesicles with
secretory products were more evident in non-SP than SP tumors.
Further, fewer blood vessels were evident in SP tumors than
ALDH1+ and ALDH12 tumors. The re-transplantation assays
showed that blood vessel density in re-transplanted pooled non-SP
generated tumors was lower than originally transplanted non-SP
cell tumors but more than originally transplanted SP cell tumors
suggesting that cells with a non-SP phenotype are capable of
inducing more blood vessels for tumor growth and survival
whereas SP cells can grow and form larger tumors with minimal
Figure 7. Levels and numbers of cytokines/chemokines produced by Cl66 alone and co-cultured Cl66 with MS-5 stromal cells. Media
were collected at day 3 from Cl66 cells alone and co-cultured Cl66 with MS-5 stromal cells; and subjected to analysis of the cytokine/chemokine
profiles. (A) Histograms show the production of chemokine(s)/cytokine(s) by Cl66 cells alone and changes influenced by co-culture with MS-5 stromal
cells. (B) Histograms demonstrate the production of chemokine(s)/cytokine(s) during in vitro interactions of Cl66 with MS-5 stromal cells.
doi:10.1371/journal.pone.0078725.g007
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blood vessel density, i.e., SP tumor cells are relatively more
resistant to lack of blood supply and hypoxia. We speculate this
reflects relative angiogenic factor production (non-SP cells) versus
relative self-renewal activities (higher for SP cells), but this requires
more detailed evaluation.
Evidence indicates that soluble factor(s) such as IL6 produced
by non-stem type cells have the capacity to convert non-stem type
cells to stem cell-type cells [42]. Also, IL6 and IL8 appear to be
important in breast tumor growth [40]. Because of this and
because of the differences in tumor BVD, we analyzed the various
cell populations for the production of soluble factors. The
tumorigenic behavior of various cell populations with stem cell
versus non-stem cell phenotypes could be a characteristic related
to heterogeneities in levels of cytokines/chemokines produced by
the differing cell populations and which influence growth of tumor
cells in their microenvironment(s). The data from this study
indicated that there were heterogeneities in functions of cell
populations with various stem phenotypes isolated from the same
population of breast cancer cells of Cl66 which may be context
dependent and based on stromal environments, factor production
or receptor expression, and signaling pathway utilization. Co-
culture of Cl66 with stromal MS-5 cells increased the levels of
multiple cytokines. However, without stromal MS-5 cells, the
intrinsic production of cytokines was limited to eight. Of these,
RANTES was the highest, with IP-10, TIMP, KC intermediate
followed by mid-level JE, MIP-2 and low levels of IFN-c, M-CSF.
A recent study of MSC (mesenchymal stromal cells) exposed to
hypoxia showed that hypoxia increased the levels of several
cytokines in the secretome [63,64].
Evidence suggests that RANTES (CCL5), one of the murine
homologues of IL8, has angiogenesis-related activities [65–68] and
CCL2 (JE or MCP-1) is indeed a potent angiogenic chemokine
[66,69–73] that acts by increasing the presence of tumor
associated macrophages (TAMs) at breast tumor sites, possibly
by elevated release of angiogenic factors and by acting directly on
endothelial cells to promote angiogenesis. Many other cytokines
that are associated with angiogenesis such as, IP-10, IFNc, MIP-
1a, IL1a, IL-2, IL-4, IL-10, IL-13, IL-17, I-TAC, MIG [74] are
found to be up-regulated after Cl66 and stromal MS-5 interactions
indicating the possible important contribution of angiogenesis
in vivo. RANTES was also proposed earlier to be considered as a
biomarker for disease progression in stage IIA breast cancer
patients [75] and currently, is being suggested as an inflammatory
mediator with pro-malignancy activities in breast cancer [76].
Recent pre-clinical and clinical studies have revealed that
RANTES is strongly associated with invasiveness [77] the
progression of breast cancer, particularly triple negative breast
cancer [78]. The interaction of CCL5 with its receptor CCR5
promotes cancer cell migration under hypoxia [79]. JE specifically
attracts monocytes in vitro and in vivo, but has no detectable effects
on neutrophils or lymphocytes. IP-10 (CXCL10) induces lympho-
cytic infiltration [80]; and may act in a paracrine manner by
affecting tumor microenvironment and in an autocrine manner by
acting on tumor cells and may play a role in tumor invasiveness
and progression [80]. Stromal MS-5 interaction induced up-
regulation of MIP-2, MIP1a, RANTES, and TIMP-1 that are
associated with tumor progression [74,81]. SDF-1 is associated
with tumor progression and metastasis. A paracrine network of
KC (CXCL1) links cancer chemoresistance and its metastasis [82].
We observed similar expression in the level of MIP-2 (CXCL2)
and TIMP-1 by Cl66 alone and also in the presence of stromal
MS-5 cell. M-CSF (an anti-inflammatory mediator) was found to
induce diverse anti-inflammatory types of macrophages, known
under the generic term M2 macrophages [83]. A more detailed
analysis of the role of soluble factor production in breast cancer
growth and metastasis is warranted because these are potential
therapeutic targets.
Although co-culture of the tumor cells with stromal cells
generally increased cytokine production, the cellular source of
these cytokines could not be determined. Also, it was difficult to
quantitate cytokine production by specific sorted stem cell
populations because of their rarity. Evaluation of these mecha-
nisms by molecular manipulations is a future challenge. Overall,
Cl66 murine breast cancer cells isolated based on different stem
cell phenotypes as well as non-stem cells exhibit functionally
heterogeneous behaviors. It will be important, in the future, to
attempt to extend these studies to human breast cancer. However,
concerns that the efficiency of tumorigenesis will be influenced by
the mismatch between the human tumor cells and mouse
microenvironment, as noted in lymphoma [16], currently cannot
be circumvented.
Supporting Information
Figure S1 Generation of tumor spheres from sorted cell
populations of Cl66 murine breast cancer cells. Tumor
spheres were obtained by culturing sorted cells from Cl66 murine
breast cancer cells in tumor sphere medium containing EGF and
bFGF. Cells were plated at a density of 1000 cells/ml.
Micrographs show the tumor spheres formed at 7–10 days.
Original magnification, 640. With MatrigelTM denoted as +M.
Addition of MatrigelTM increased the size of spheres with SP,
ALDH1+, and CD34high when compared with their respective
non-stem cell populations.
(TIF)
Figure S2 Generation of agar colony from sorted cell
populations of Cl66 murine breast cancer cells. Agar
colonies were obtained by culturing sorted cells from Cl66 murine
breast cancer cells in soft-agar containing complete DMEM media
with and without MatrigelTM. Phase-contrast images show the
agar colonies formed by cell populations with stem and non-stem
cell phenotypes after 2 weeks. Original magnification, 1006. With
MatrigelTM denoted as +M.
(TIF)
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